Literature DB >> 9840931

Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).

M Schmid1, D Malicki, T Nobori, M D Rosenbach, K Campbell, D A Carson, C J Carrera.   

Abstract

Homozygous deletions of the tumor suppressor gene p16INK4A and deficiency of methylthioadenosine phosphorylase (MTAP), both located on chromosome 9p21, have been independently reported in non-small cell lung cancer (NSCLC). To determine the frequency of co-deletion of these two genes, we investigated 50 samples of primary NSCLC using a quantitative PCR-ELISA. All specimens were fixed in formalin, paraffin embedded and stored until assayed. Histologic subtypes included 25 adenocarcinomas (50%), 21 squamous cell carcinomas (42%) and four large cell carcinomas (8%). Homozygous deletions of MTAP exon 8 could be detected in 19 of 50 NSCLC samples (38%). Adenocarcinoma (11 of 25, 44%) showed a higher deletion frequency than squamous cell carcinoma (six of 21, 29%). In contrast, homozygous p16INK4A deletions were detected in only nine of 50 (18%) samples using specific primers for p16INK4A exon 1alpha. No difference between the histological subtypes and p16INK4A deletion frequency was observed. We further investigated the ten samples with MTAP deletions but intact p16INK4A exon 1alpha with primers specific for p16INK4A exon 3, the exon nearest to MTAP exon 8. Interestingly, none of the ten samples had deletion of the p16INK4A exon 3 coding region. Fine mapping analysis performed in ten samples showed a frequent breakpoint between MTAP exon 4 and exon 5. In addition, p16 protein expression could not be detected in five out of six samples with intact p16 but deleted MTAP locus. These data show a high frequency of homozygous MTAP deletions in NSCLC which is associated with detectable co-deletion of p16INK4A in only half of the cases. This result suggests the existence either of another tumor suppressor gene telomeric of p16INK4A or of deletions involving 3'-untranslated (3'-UTR) regulatory regions of p16INK4A that can interfere with its expression or function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840931     DOI: 10.1038/sj.onc.1202205

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

Review 1.  Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer.

Authors:  Thai Q Tran; Xazmin H Lowman; Mei Kong
Journal:  Clin Cancer Res       Date:  2017-04-12       Impact factor: 12.531

2.  Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma.

Authors:  Yuwaraj Kadariya; Bu Yin; Baiqing Tang; Susan A Shinton; Eoin P Quinlivan; Xiang Hua; Andres Klein-Szanto; Tahseen I Al-Saleem; Craig H Bassing; Richard R Hardy; Warren D Kruger
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.

Authors:  Inês Crespo; Ana Luísa Vital; Ana Belen Nieto; Olinda Rebelo; Hermínio Tão; Maria Celeste Lopes; Catarina Resende Oliveira; Pim J French; Alberto Orfao; María Dolores Tabernero
Journal:  J Mol Diagn       Date:  2011-08-30       Impact factor: 5.568

4.  Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine.

Authors:  Baiqing Tang; Hyung-Ok Lee; Serim S An; Kathy Q Cai; Warren D Kruger
Journal:  Cancer Res       Date:  2018-05-29       Impact factor: 12.701

5.  Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.

Authors:  Baiqing Tang; Joseph R Testa; Warren D Kruger
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

6.  Chemical genetic screening for compounds that preferentially inhibit growth of methylthioadenosine phosphorylase (MTAP)-deficient Saccharomyces cerevisiae.

Authors:  Yuwaraj Kadariya; Baiqing Tang; Cynthia B Myers; Jami Fukui; Jeffrey R Peterson; Warren D Kruger
Journal:  J Biomol Screen       Date:  2010-12-03

Review 7.  Long Non-coding RNA ANRIL and Polycomb in Human Cancers and Cardiovascular Disease.

Authors:  Francesca Aguilo; Serena Di Cecilia; Martin J Walsh
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

8.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

Authors:  Martin L Sos; Kathrin Michel; Thomas Zander; Jonathan Weiss; Peter Frommolt; Martin Peifer; Danan Li; Roland Ullrich; Mirjam Koker; Florian Fischer; Takeshi Shimamura; Daniel Rauh; Craig Mermel; Stefanie Fischer; Isabel Stückrath; Stefanie Heynck; Rameen Beroukhim; William Lin; Wendy Winckler; Kinjal Shah; Thomas LaFramboise; Whei F Moriarty; Megan Hanna; Laura Tolosi; Jörg Rahnenführer; Roel Verhaak; Derek Chiang; Gad Getz; Martin Hellmich; Jürgen Wolf; Luc Girard; Michael Peyton; Barbara A Weir; Tzu-Hsiu Chen; Heidi Greulich; Jordi Barretina; Geoffrey I Shapiro; Levi A Garraway; Adi F Gazdar; John D Minna; Matthew Meyerson; Kwok-Kin Wong; Roman K Thomas
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

9.  A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.

Authors:  Hedy Lee Kindler; Howard A Burris; Alan B Sandler; Ira Anton Oliff
Journal:  Invest New Drugs       Date:  2008-07-11       Impact factor: 3.850

10.  Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours.

Authors:  J Mora; M Alaminos; C de Torres; P Illei; J Qin; N-K V Cheung; W L Gerald
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.